FDA Approves ‘Breakthough’ Drug to Prevent HIV

Food and Drug Department confirmed a preventive HIV drug accepted only as a solution.

On Wednesday afternoon FDA Gilead sciences confirmed as a form of pre-exposure prevention (preparation). In clinical trials, it was shown to be highly effective in preventing HIV infection when taken twice a year. At the same time, lawyers ensure that Gilead and US officials provide a wide range of medicine for the public.

“Preparing is one of the most necessary tools for the end of the HIV epidemic. It is a long-term choice to keep a long-term hint for many years of relying,” Kevin Robert Frost, AMFAR CEO, ADD, in a statement issued for AIDS research. “However, this remarkable drug will be only as effective as it is accessible and affordable.”

FDA first confirmed Lenacapavir in 2022 as an antiretroviral treatment for HIV, sold under the name of Sunlenca. This was the first approved treatment of a Roman drug class for HIV medications directly targeting the virus directly to HIV. Only this made Lenacapavir’s vital progress because it could treat infections that are resistant to other drugs. However, the biggest potential of the drug can be created as vaccinations to prevent the virus to prevent a point.

A year ago, Gilead released The results of the purpose of 1 Stage III testing of Lenacapavir in ciscender women in cisgender women in the 1st week. The drug is ahead of daily preparation choices with 100% prevention rate. Then the experiment is indicator Cisgender men, transgender men and women and women and gender dual individuals prevent 99.9% prevention. The success of the drug was so impressive that scientific journal named As the year of the year. Gilead is also now reading If an annual dose can be effective.

As is monumental as the arrival of the Lenacapavir’s preparation, its value can create a problem in its value – especially the authority of Gilead. The company has been a long time High and often growing list prices For previous preparation drugs and there are has been severe resistance Attempts to reduce these prices in the United States and others (today as wellA monthly supply in the Truva may be up to $ 2,000 without insurance). Although Gilead is also available, it was accused of delaying the development of cheaper generators; In 2023 the company is an issue Class action claim over these allegations.

NBC News declare The preparation version of Lenacapavir, sold under the YEZTGO brand on Wednesday, will be a list of $ 14.109 per month or $ 2,352. Gilead in FDA approval declared It works with other payers in order to provide extensive insurance coverage with insurers, health systems and other payers. ” Yeztugo will set up programs designed to reduce out of pocket expenses, for some compatible people or for people who are uninsured to $ 0.

When these departments will have to say that the medication will be widely affordable and Americans and as a result to be accessible to everyone in the world.

“AMAR calls on the Gilead science and the US government to do everything as much as many people who want to Lenacapavir,” he said.